Group 1 - The "Beijing Universal Health Insurance" project will upgrade its special drug list from 106 to 121 drugs in 2025, allowing for reimbursement of more special drugs [1] - The new special drug list will be effective from June 10, 2025, and retroactive compensation will be available for eligible claims from January 1 to June 9, 2025 [1] - The updated list retains drugs already included in the medical insurance directory, such as six drugs including Vitekai, and five drugs with certain indications that have been added to the medical insurance directory [1] Group 2 - The new special drug list will add 15 new drugs, focusing on high-incidence cancer medications and covering the entire treatment cycle and target drug types [2] - The list will expand the indications for ten drugs, including Cuirida, based on the new medication guidelines, allowing for a broader range of reimbursable indications [2] - The list will replace drugs that have no claims, such as Hejie Kang, with newly listed non-medical insurance drugs like Yihe Lai, enabling more patients to access effective medications [2]